Author(s): No authors listed
Abstract Share this page
Abstract Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C virus (HCV) inhibitors. It is being developed by Merck & Co. as part of a combination therapy regimen for the treatment of HCV infections. In two phase III trials, the HCV RESPOND-2 and HCV SPRINT-2 trials, the primary endpoints were met. Phase III development continues in the US, Europe, and Canada. This review looks at the key development milestones and therapeutic trials of this drug.
This article was published in Drugs R D
and referenced in Journal of Antivirals & Antiretrovirals